Even if Apabetalone is unsuccessful as a covid intervention (which would be surprising) this study suggesting multiple types of post covid blood vasculature insults would seem to suggest that Apabetalone could have a very large role in post covid treatment. The company's own research as well as the Australian and UofN work would seem to support getting down this road as soon as possible. If Don was any kind of a business man this would seem to be one more tool to facilitate a sale of the company to a cash rich pharma looking to extend their cash generation from covid (re Toinv's last post). The current heart indications along with a covid and/or post covid therapy would seem to be an attractive package.